Rheumatoid Arthritis
Selective B cell therapy rituximab for treating rheumatoid arthritis approved in Europe
Published in Immunotherapy Weekly, August 9th, 2006
MabThera in combination with methotrexate is indicated for the treatment of adult patients with severe active rheumatoid arthritis who have had an inadequate response or are intolerant to current treatment options including one or more tumor necrosis factor (TNF) inhibitors. MabThera is the first selective B cell therapy for RA with a fundamentally different treatment approach.
B cells play a key role in driving the RA disease process and MabThera is thought to break this process so preventing disease...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Immunotherapy Weekly
Source: Immunotherapy Weekly (2006-08-09)
More Articles from Immunotherapy Weekly
- Allergy & Immunology
Exposure to concentrated ambient particles may aggravate allergic airway disease - Asthma
Inhaled corticosteroids and antileukotriene drugs may be best treatment for asthma - Influenza Vaccine
Efficacy of influenza vaccine is decreased in systemic lupus erythematosus patients - Vaccine Adjuvant
Influenza vaccine with surf clam microparticle adjuvant protects against infection - Adverse Drug Reaction
Severe liver disease is associated with prolonged antiretroviral drug exposure - Allergy & Immunology
Allergic inflammation is modified by different bacterial ligands in a rhinitis model - More from this issue of Immunotherapy Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
